Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free NKGN Stock Alerts

NKGen Biotech (NKGN) Competitors

NKGen Biotech logo
$0.0021 -0.01 (-79.00%)
As of 09/3/2026 03:43 PM Eastern
Compare

NKGN vs. HEPA, NMTR, EVFM, PRFX, and ATHX

Should you buy NKGen Biotech stock or one of its competitors? NKGen Biotech's main competitors and comparable companies include Hepion Pharmaceuticals (HEPA), 9 Meters Biopharma (NMTR), Evofem Biosciences (EVFM), PainReform (PRFX), and Athersys (ATHX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NKGen Biotech compare to Hepion Pharmaceuticals?

NKGen Biotech (NYSE:NKGN) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Hepion Pharmaceuticals Neutral

NKGen Biotech's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Hepion Pharmaceuticals N/A -812.56%-207.31%

NKGen Biotech has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

NKGen Biotech is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Hepion PharmaceuticalsN/AN/A-$48.93M-$72.15N/A

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by company insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

NKGen Biotech beats Hepion Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

How does NKGen Biotech compare to 9 Meters Biopharma?

9 Meters Biopharma (NASDAQ:NMTR) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

22.3% of 9 Meters Biopharma shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 2.4% of 9 Meters Biopharma shares are owned by company insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

9 Meters Biopharma has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market.

NKGen Biotech is trading at a lower price-to-earnings ratio than 9 Meters Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
9 Meters BiopharmaN/AN/A-$43.77M-$3.46N/A
NKGen BiotechN/AN/A-$82.94M-$1.68N/A

In the previous week, 9 Meters Biopharma's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
9 Meters Biopharma Neutral
NKGen Biotech Neutral

NKGen Biotech's return on equity of 0.00% beat 9 Meters Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
9 Meters BiopharmaN/A -584.97% -159.45%
NKGen Biotech N/A N/A -479.36%

Summary

9 Meters Biopharma and NKGen Biotech tied by winning 4 of the 8 factors compared between the two stocks.

How does NKGen Biotech compare to Evofem Biosciences?

Evofem Biosciences (NASDAQ:EVFM) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

Evofem Biosciences has higher revenue and earnings than NKGen Biotech. Evofem Biosciences is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evofem Biosciences$11.39M0.09$52.98M-$0.13N/A
NKGen BiotechN/AN/A-$82.94M-$1.68N/A

Evofem Biosciences has a beta of -1.31, indicating that its stock price is 231% less volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

In the previous week, Evofem Biosciences had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Evofem Biosciences and 0 mentions for NKGen Biotech. Evofem Biosciences' average media sentiment score of 0.67 beat NKGen Biotech's score of 0.00 indicating that Evofem Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Evofem Biosciences Positive
NKGen Biotech Neutral

NKGen Biotech has a net margin of 0.00% compared to Evofem Biosciences' net margin of -46.42%. NKGen Biotech's return on equity of 0.00% beat Evofem Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Evofem Biosciences-46.42% -91.97% -61.93%
NKGen Biotech N/A N/A -479.36%

0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Evofem Biosciences and NKGen Biotech tied by winning 6 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to PainReform?

NKGen Biotech (NYSE:NKGN) and PainReform (NASDAQ:PRFX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, PainReform had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for PainReform and 0 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 0.00 equaled PainReform'saverage media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
PainReform Neutral

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
PainReform N/A N/A N/A

NKGen Biotech has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, PainReform has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
PainReform
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

PainReform has higher revenue and earnings than NKGen Biotech. PainReform is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
PainReform$20K42.60-$5.02M-$736.66N/A

Summary

PainReform beats NKGen Biotech on 7 of the 10 factors compared between the two stocks.

How does NKGen Biotech compare to Athersys?

NKGen Biotech (NYSE:NKGN) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Athersys has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Athersys$146K0.00-$72.53M-$2.03N/A

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Athersys N/A N/A -223.03%

NKGen Biotech has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Athersys has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market.

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Athersys Neutral

Summary

NKGen Biotech beats Athersys on 5 of the 8 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

Export
MetricNKGen BiotechPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$1.31M$12.25B$7.26B$23.50B
Dividend YieldN/A2.59%2.53%3.73%
P/E Ratio0.00787.27273.2929.39
Price / SalesN/A755.95621.7920.98
Price / CashN/A94.8077.8232.15
Price / Book0.0012.3113.087.63
Net Income-$82.94M$2.82B$3.47B$1.07B
7 Day PerformanceN/A2.59%0.52%-0.16%
1 Month PerformanceN/A6.95%5.63%-0.46%
1 Year PerformanceN/A9.44%25.31%13.09%

NKGen Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
N/A$0.00
-79.0%		N/A-98.4%$1.31MN/AN/AN/A
HEPA
Hepion Pharmaceuticals
N/A$0.10
+79.2%		N/A+0.0%$1.09MN/AN/A20
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$1.04MN/AN/A20
EVFM
Evofem Biosciences
N/A$0.01
-8.5%		N/A-21.1%$994K$11.39MN/A120
PRFX
PainReform
0.359 of 5 stars		$0.96
-2.6%		N/A-86.1%$860K$20KN/A4

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Are you leaving Social Security money on the table?
Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....
Money Pickle | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel